| 2027-03-01in 188 d | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. | AZNAstraZeneca | — | Lung Cancer | Active, not recruiting |
| 2027-03-01in 188 d | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | NVONovo Nordisk A/S | Phase 3 | Obesity | Active, not recruiting |
| 2027-03-01in 188 d | A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market | PFEPfizer | — | Pneumococcal Disease | Recruiting |
| 2027-03-01in 188 d | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis | SXTP60 Degrees Pharmaceuticals LLC | Phase 2 | Babesiosis | Recruiting |
| 2027-03-01in 188 d | Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes | TNDMTandem Diabetes Care, Inc. | Not applicable | Type 1 Diabetes | Active, not recruiting |
| 2027-03-05in 192 d | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. | PFEPfizer | Phase 2 | Hidradenitis Suppurativa | Recruiting |
| 2027-03-05in 192 d | A Phase 1, First-in-human Study of VX-433 | VRTXVertex Pharmaceuticals Incorporated | Phase 1 | Narcolepsy | Recruiting |
| 2027-03-06in 193 d | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | MRNAModernaTX, Inc. | Phase 2 | Cytomegalovirus Infection | Active, not recruiting |
| 2027-03-08in 195 d | A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | PFEPfizer | Phase 2 | Asthma | Recruiting |
| 2027-03-10in 197 d | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. | FBRXForte Biosciences, Inc. | Phase 1 | Alopecia Areata | Recruiting |
| 2027-03-10in 197 d | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | GSKIDRX, Inc., a wholly owned subsidiary of GSK, LLC | Phase 1 | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer | Active, not recruiting |
| 2027-03-11in 198 d | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | BMYBristol-Myers Squibb | Phase 3 | Renal Cell Carcinoma | Active, not recruiting |
| 2027-03-11in 198 d | A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | BMYBristol-Myers Squibb | — | Psoriasis | Active, not recruiting |
| 2027-03-12in 199 d | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | TVTXTravere Therapeutics, Inc. | Phase 2 | Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome | Recruiting |
| 2027-03-12in 199 d | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | VRTXVertex Pharmaceuticals Incorporated | Phase 1/2 | Type 1 Diabetes | Active, not recruiting |
| 2027-03-13in 200 d | A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function | PFEPfizer | Phase 1 | Renal Impairment, Healthy | Recruiting |
| 2027-03-13in 200 d | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | RYTMRhythm Pharmaceuticals, Inc. | Phase 3 | Obesity | Recruiting |
| 2027-03-15in 202 d | A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France | BMYBristol-Myers Squibb | — | Melanoma | Active, not recruiting |
| 2027-03-16in 203 d | Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | SNYSanofi | Phase 4 | Asthma | Active, not recruiting |
| 2027-03-17in 204 d | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | PFEPfizer | Phase 3 | Ulcerative Colitis | Active, not recruiting |
| 2027-03-18in 205 d | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | BMYBristol-Myers Squibb | Phase 2 | Alzheimer's Disease | Active, not recruiting |
| 2027-03-22in 209 d | A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants | INSMInsmed Incorporated | Phase 1 | Healthy Volunteers | Not yet recruiting |
| 2027-03-22in 209 d | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | REGNRegeneron Pharmaceuticals | Phase 3 | Melanoma | Recruiting |
| 2027-03-23in 210 d | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | AZNAstraZeneca | Phase 2 | Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer | Active, not recruiting |
| 2027-03-23in 210 d | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | VRTXVertex Pharmaceuticals Incorporated | Phase 1 | Cystic Fibrosis | Recruiting |
| 2027-03-25in 212 d | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | REGNRegeneron Pharmaceuticals | Phase 1/2 | Ovarian Cancer | Recruiting |
| 2027-03-25in 212 d | Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | REGNRegeneron Pharmaceuticals | — | Chronic Rhinosinusitis | Active, not recruiting |
| 2027-03-25in 212 d | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | REGNRegeneron Pharmaceuticals | Phase 1 | End-Stage Kidney Disease (ESKD) | Not yet recruiting |
| 2027-03-25in 212 d | A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | SNYSanofi | Phase 3 | Hemophilia | Active, not recruiting |
| 2027-03-25in 212 d | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy | VRTXVertex Pharmaceuticals Incorporated | Phase 2 | Diabetic Peripheral Neuropathic Pain | Recruiting |
| 2027-03-26in 213 d | A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | IPN.PAIpsen | Phase 2 | Cervical Dystonia | Recruiting |
| 2027-03-27in 214 d | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | INCYIncyte Corporation | Phase 1 | Solid Tumors | Active, not recruiting |
| 2027-03-27in 214 d | A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | NVONovo Nordisk A/S | — | Type 2 Diabetes | Recruiting |
| 2027-03-29in 216 d | A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone | BIIBBiogen | — | Postpartum Depression | Recruiting |
| 2027-03-29in 216 d | A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses | BMYBristol-Myers Squibb | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-03-30in 217 d | Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2 | PFSAProfusa, Inc. | Not applicable | Peripheral Artery Disease | Active, not recruiting |
| 2027-03-30in 217 d | Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) | REGNRegeneron Pharmaceuticals | — | Atopic Dermatitis | Active, not recruiting |
| 2027-03-30in 217 d | Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh | TELATela Bio Inc | Not applicable | Hernia, Ventral, Hernia, Inguinal | Recruiting |
| 2027-03-31in 218 d | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | 000100.KSYuhan Corporation | — | Hypertension | Active, not recruiting |
| Mar 2027≤ 218 d | A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants | 000100.KSYuhan Corporation | Phase 1 | Healthy Participants | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps | 068270.KSCelltrion | — | Rheumatoid Arthritis | Active, not recruiting |
| Mar 2027≤ 218 d | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | 4151.TKyowa Kirin Co., Ltd. | Phase 2 | Acute Myeloid Leukemia | Recruiting |
| 2027-03-31in 218 d | Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 4519.TChugai Pharmaceutical | Phase 1 | Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP) | Recruiting |
| 2027-03-31in 218 d | Study of E7386 in Participants With Selected Advanced Neoplasms | 4523.TEisai Inc. | Phase 1 | Advanced Neoplasms | Active, not recruiting |
| 2027-03-31in 218 d | A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | 4523.TEisai Co., Ltd. | Phase 1 | Solid Tumors | Active, not recruiting |
| 2027-03-31in 218 d | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 4523.TEisai Inc. | Phase 1/2 | Endometrial Cancer | Active, not recruiting |
| 2027-03-31in 218 d | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | 4523.TEisai Co., Ltd. | Phase 1/2 | Solid Tumors | Active, not recruiting |
| 2027-03-31in 218 d | A Study of Olverembatinib in SDH-deficient GIST. | AAPGAscentage Pharma Group Inc. | Phase 3 | GIST | Recruiting |
| Mar 2027≤ 218 d | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | ABBVAbbVie | Phase 3 | Bipolar Disorder | Recruiting |
| Mar 2027≤ 218 d | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada | ABBVAbbVie | — | Acute Myeloid Leukemia | Active, not recruiting |
| Mar 2027≤ 218 d | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ABBVAbbVie | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | ABBVAbbVie | Phase 3 | Crohn's Disease | Active, not recruiting |
| Mar 2027≤ 218 d | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) | ABBVAbbVie | Phase 2 | Urothelial Carcinoma | Active, not recruiting |
| Mar 2027≤ 218 d | Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | ABBVAbbVie | — | Advanced Parkinson Disease | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Mar 2027≤ 218 d | A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity | ABBVAbbVie | Phase 1 | Obesity | Recruiting |
| Mar 2027≤ 218 d | Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks | ABBVAbbVie | — | Migraine | Recruiting |
| Mar 2027≤ 218 d | Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries | ABBVAbbVie | — | Ovarian Cancer | Recruiting |
| Mar 2027≤ 218 d | A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema | ABBVAbbVie | — | Diabetic Macular Edema | Not yet recruiting |
| Mar 2027≤ 218 d | A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines | ABBVAbbVie | Phase 1 | Glabellar Lines | Not yet recruiting |
| 2027-03-31in 218 d | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | ADCTADC Therapeutics S.A. | Phase 1 | Non-Hodgkin Lymphoma | Active, not recruiting |
| 2027-03-31in 218 d | Cryoablation for Monomorphic Ventricular Tachycardia (VTS) | ADGMAdagio Medical | Not applicable | Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic | Recruiting |
| Mar 2027≤ 218 d | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | ALGSAligos Therapeutics | Phase 2 | Chronic Hepatitis B Infection | Active, not recruiting |
| Mar 2027≤ 218 d | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | ALLRAllarity Therapeutics | Phase 2 | Ovarian Cancer | Recruiting |
| 2027-03-31in 218 d | A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers | AMGNAmgen | Phase 1 | Healthy Participants | Recruiting |
| Mar 2027≤ 218 d | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | AURAAura Biosciences | Phase 1 | Bladder Cancer | Active, not recruiting |
| 2027-03-31in 218 d | CLL Therapy Approaches in Russia | AZNAstraZeneca | — | Chronic Lymphocytic Leukemia | Active, not recruiting |
| 2027-03-31in 218 d | SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) | AZNAstraZeneca | — | Systemic Lupus Erythematosus | Active, not recruiting |
| 2027-03-31in 218 d | Study for AZD4360 in Participants With Advanced Solid Tumours | AZNAstraZeneca | Phase 1/2 | Gastric Cancer | Active, not recruiting |
| 2027-03-31in 218 d | PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort | AZNAstraZeneca | — | Prostate Cancer | Not yet recruiting |
| 2027-03-31in 218 d | A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | AZNAstraZeneca | — | Type 2 Diabetes | Recruiting |
| 2027-03-31in 218 d | A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet) | AZNAstraZeneca | Not applicable | Lung Cancer | Recruiting |
| Mar 2027≤ 218 d | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets | BMEABiomea Fusion Inc. | Phase 2 | Type 2 Diabetes | Recruiting |
| Mar 2027≤ 218 d | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | BMRNBioMarin Pharmaceutical | Phase 2 | Noonan Syndrome | Recruiting |
| 2027-03-31in 218 d | Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis | BMYBristol-Myers Squibb | — | Ulcerative Colitis | Recruiting |
| Mar 2027≤ 218 d | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | BPTHBio-Path Holdings, Inc. | Phase 1 | Acute Myeloid Leukemia | Recruiting |
| 2027-03-31in 218 d | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | CGONCG Oncology, Inc. | Phase 2 | High-Risk Non-Muscle-Invasive Bladder Cancer | Recruiting |
| Mar 2027≤ 218 d | A Study of CDX-622 in Participants With Mild to Moderate Asthma | CLDXCelldex Therapeutics | Phase 1 | Mild to Moderate Asthma | Recruiting |
| Mar 2027≤ 218 d | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | COGTCogent Biosciences, Inc. | Phase 1/2 | Cholangiocarcinoma | Active, not recruiting |
| Mar 2027≤ 218 d | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | DNLIDenali Therapeutics Inc. | Phase 2 | Parkinson's Disease | Active, not recruiting |
| Mar 2027≤ 218 d | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | EWTXEdgewise Therapeutics, Inc. | Phase 2 | Duchenne Muscular Dystrophy | Active, not recruiting |
| Mar 2027≤ 218 d | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | FDMT4D Molecular Therapeutics | Phase 1/2 | Age-Related Macular Degeneration | Recruiting |
| Mar 2027≤ 218 d | Investigating Autimia, a Digital Intervention for Patients With Autism Spectrum Disorder | GAIAGaia AG | Not applicable | Autism Spectrum Disorder | Recruiting |
| Mar 2027≤ 218 d | Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children | GILDGilead Sciences | Phase 2 | HIV | Recruiting |
| Mar 2027≤ 218 d | Study of GS-0151 in Participants With Rheumatoid Arthritis | GILDGilead Sciences | Phase 1 | Rheumatoid Arthritis | Recruiting |
| 2027-03-31in 218 d | REFLECT Scoliosis System Post Approval Study | GMEDGlobus Medical Inc | Not applicable | Idiopathic Scoliosis | Recruiting |
| 2027-03-31in 218 d | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | HURATuHURA Biosciences, Inc. | Phase 2/3 | Advanced Or Metastatic Merkel Cell Carcinoma | Recruiting |
| Mar 2027≤ 218 d | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | IONSIonis Pharmaceuticals, Inc. | Phase 3 | Severe Hypertriglyceridemia | Active, not recruiting |
| 2027-03-31in 218 d | Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) | IPN.PAIpsen | — | Renal Cell Carcinoma | Active, not recruiting |
| Mar 2027≤ 218 d | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | LLYEli Lilly and Company | Phase 1 | Solid Tumors | Active, not recruiting |
| Mar 2027≤ 218 d | A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | LLYEli Lilly and Company | Phase 2 | Obesity | Recruiting |
| Mar 2027≤ 218 d | A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | LLYEli Lilly and Company | Phase 2 | Severe Hypertriglyceridemia | Recruiting |
| Mar 2027≤ 218 d | A Study of LY4515100 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Recruiting |
| Mar 2027≤ 218 d | A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | LLYEli Lilly and Company | Phase 1 | Hepatic Insufficiency | Recruiting |
| 2027-03-31in 218 d | Zephyr Valve Japan Post-Marketing Surveillance | LUNGPulmonx Corporation | — | COPD | Recruiting |
| Mar 2027≤ 218 d | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | MDGLMadrigal Pharmaceuticals, Inc. | Phase 3 | Non-Alcoholic Fatty Liver Disease | Active, not recruiting |
| Mar 2027≤ 218 d | Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia | MGTXMeiraGTx, LLC | — | Radiation-induced Xerostomia | Active, not recruiting |
| Mar 2027≤ 218 d | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | MNKDMannkind Corporation | Phase 2 | Type 1 Diabetes | Recruiting |
| 2027-03-31in 218 d | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | MSLESatellos Bioscience, Inc. | Phase 2 | Duchenne Muscular Dystrophy | Recruiting |
| Mar 2027≤ 218 d | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | NUVBNuvation Bio Inc. | Phase 1/2 | Solid Tumors | Active, not recruiting |
| Mar 2027≤ 218 d | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | NVCTNuvectis Pharma, Inc. | Phase 1 | Solid Tumors | Recruiting |
| Mar 2027≤ 218 d | Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis | OCGNOcugen | Phase 1/2 | Retinitis Pigmentosa, Leber Congenital Amaurosis | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | OCULOcular Therapeutix, Inc. | Phase 3 | Non-Proliferative Diabetic Retinopathy | Recruiting |
| Mar 2027≤ 218 d | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | ONCBeOne Medicines | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Active, not recruiting |
| Mar 2027≤ 218 d | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | PCVXVaxcyte, Inc. | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| Mar 2027≤ 218 d | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | PCVXVaxcyte, Inc. | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| Mar 2027≤ 218 d | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | PEPGPepGen Inc | Phase 2 | Myotonic Dystrophy 1 | Recruiting |
| 2027-03-31in 218 d | Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections | PFEPfizer | Phase 2 | Gram-negative Bacterial Infections | Recruiting |
| 2027-03-31in 218 d | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | PFEPfizer | Phase 3 | Vitiligo | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | PMVPPMV Pharmaceuticals, Inc | Phase 1 | Solid Tumors | Recruiting |
| Mar 2027≤ 218 d | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | PSTVPlus Therapeutics | Phase 1 | Glioma | Not yet recruiting |
| 2027-03-31in 218 d | Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients | REGNRegeneron Pharmaceuticals | — | Lung Cancer | Active, not recruiting |
| 2027-03-31in 218 d | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | RVMDRevolution Medicines, Inc. | Phase 1 | Lung Cancer | Active, not recruiting |
| 2027-03-31in 218 d | Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | SNYSanofi | — | Atopic Dermatitis | Active, not recruiting |
| Mar 2027≤ 218 d | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | SOBI.STSwedish Orphan Biovitrum | Phase 3 | Hemophilia A | Recruiting |
| Mar 2027≤ 218 d | A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | SPTXSeaport Therapeutics | Phase 2 | Major Depressive Disorder | Recruiting |
| 2027-03-31in 218 d | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | SRPTSarepta Therapeutics, Inc. | Phase 4 | Duchenne Muscular Dystrophy | Not yet recruiting |
| Mar 2027≤ 218 d | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | STOKStoke Therapeutics, Inc | Phase 3 | Dravet Syndrome | Recruiting |
| 2027-03-31in 218 d | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | TNGXTango Therapeutics, Inc. | Phase 1/2 | Lung Cancer | Recruiting |
| Mar 2027≤ 218 d | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | TVTXTravere Therapeutics, Inc. | Phase 4 | Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant | Active, not recruiting |
| Mar 2027≤ 218 d | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | URGNUroGen Pharma Ltd. | Phase 3 | Urothelial Carcinoma | Recruiting |
| Mar 2027≤ 218 d | ADAPT - A Patient Registry of the Real-world Use of Orenitram® | UTHRUnited Therapeutics | — | Pulmonary Arterial Hypertension | Active, not recruiting |
| Mar 2027≤ 218 d | Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | VNDAVanda Pharmaceuticals | Phase 1/2 | Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD) | Active, not recruiting |
| Mar 2027≤ 218 d | Dymista in Chinese Adolescents | VTRSViatris Inc. | Phase 4 | Allergic Rhinitis Due to Allergens | Recruiting |
| Mar 2027≤ 218 d | MDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads | ZBHZimmer Biomet | — | Hip Arthritis, Hip Disease, Hip Fractures, Hip Injuries, Hip Pain Chronic | Enrolling by invitation |
